Kos Biotechnology Partners Announces Investment in Fathom Therapeutics to Advance Novel, AI-Driven Drug Discovery Platform
Kos joins Sutter Hill Ventures and other leading investors in backing Fathom Therapeutics's pioneering physics- and AI-powered drug discovery platform NEW YORK and ATHENS, Greece, Nov. 6, 2026 /PRNewswire/ -- Kos Biotechnology Partners ("Kos"), a global life sciences investment firm...
Covered in this story
Call it yourself
No calls on $NOV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on NOV →Dalsna Finance is currently tracking 104 stories mentioning NOV, the earliest published 7 Oct 2025.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.